Abstract
Cystic kidney disease (CyKD) is a predominantly familial disease. Gene discovery has been led by family-based and candidate gene studies, limiting the ascertainment of additional genome-wide variants involved. Taking whole genome sequencing data from the 100,000 Genomes Project, we used hypothesis-free approaches to systematically characterize and quantify genetic contributors to CyKD across variant types and the allelic spectrum in 1,209 cases and 26,096 ancestry-matched controls. In 82.3% CyKD cases a likely disease-causing monogenic variant was identified. There was an enrichment of rare coding, splicing and structural variants in known CyKD genes, and novel gene-based signals in COL4A3 and (monoallelic) PKHD1. The risks of these variants to CyKD were quantified, with lower risk seen in more recently described genes. Meta-analysis of common variants across four international biobanks did not reveal any associations. Common variants accounted for 3-9% of the heritability of CyKD across three European ancestry cohorts. This represents an unbiased examination of the genetic architecture of a national CyKD cohort using robust statistical methodology. We have quantified the contribution of coding, non-coding, and structural variants to CyKD, and the small contribution of common variants to its heritability. These findings will inform genetic testing and counselling strategies in the clinic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
OSA is funded by an MRC Clinical Research Training Fellowship (MR/S021329/1). MYC is funded by a Kidney Research UK Clinical Research Fellowship (TF_004_20161125). DPG is supported by the St Peters Trust for Kidney, Bladder and Prostate Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the 100,000 genome project was granted by the Research Ethics Committee for East of England Cambridge South (REC Ref: 14/EE/1112).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Title changed to "Quantifying variant contributions in cystic kidney disease using national-scale whole genome sequencing"
Data Availability
All data produced in the present work are contained in the manuscript and online at https://zenodo.org/records/10613736
